turoctocog alfa

The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).

Form: powder for injection solution

ATC: B02BD02

Manufacturer: A/S Novo Nordisk (preparation, filling in primary packaging, lyophilization and testing of finished medicinal product, quality control (microbiological testing) of finished medicinal product; quality control of finished medicinal product; labeling and secondary packaging of finished medicinal product, addition of scale to injection syringe); responsible for batch release of finished medicinal product

The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).

Form: powder for injection solution

ATC: B02BD02

Manufacturer: A/S Novo Nordisk (preparation, filling in primary packaging, lyophilization and testing of finished medicinal product, quality control (microbiological testing) of finished medicinal product; quality control of finished medicinal product; labeling and secondary packaging of finished medicinal product, addition of scale to injection syringe); responsible for batch release of finished medicinal product

The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).

Form: powder for injection solution

ATC: B02BD02

Manufacturer: A/S Novo Nordisk (preparation, filling in primary packaging, lyophilization and testing of finished medicinal product, quality control (microbiological testing) of finished medicinal product; quality control of finished medicinal product; labeling and secondary packaging of finished medicinal product, addition of scale to injection syringe); responsible for batch release of finished medicinal product

The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (a disease caused by a deficiency of factor VIII).

Form: powder for injection solution

ATC: B02BD02

Manufacturer: A/S Novo Nordisk (preparation, filling in primary packaging, lyophilization and testing of finished medicinal product, quality control (microbiological testing) of finished medicinal product; quality control of finished medicinal product; labeling and secondary packaging of finished medicinal product, addition of scale to injection syringe); responsible for batch release of finished medicinal product

The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).

Form: powder for injection solution

ATC: B02BD02

Manufacturer: A/S Novo Nordisk (preparation, filling in primary packaging, lyophilization and testing of finished medicinal product, quality control (microbiological testing) of finished medicinal product; quality control of finished medicinal product; labeling and secondary packaging of finished medicinal product, addition of scale to injection syringe); responsible for batch release of finished medicinal product

The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).

Form: powder for injection solution

ATC: B02BD02

Manufacturer: A/S Novo Nordisk (preparation, filling in primary packaging, lyophilization and testing of finished medicinal product, quality control (microbiological testing) of finished medicinal product; quality control of finished medicinal product; labeling and secondary packaging of finished medicinal product, addition of scale to injection syringe); responsible for batch release of finished medicinal product